Yahoo · Sep 7, 2026
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products.

